Login to Your Account



Trius 'Establishes' Key Endpoints for its Tedizolid Phase III Trial

By Staff Reports


Thursday, February 14, 2013
San Diego-based Trius Therapeutics Inc. said the results from its first pivotal Phase III study of tedizolid phosphate (TR-701) vs. linezolid (Zyvox) completed in 2011 (ESTABLISH 1), have been published in the Journal of the American Medical Association (JAMA).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription